Scienture Posts 256% Sequential Revenue Surge on Arbli and REZENOPY Growth

  • Scienture reported $1.22M in preliminary Q3 2026 revenue, up 256% sequentially from $344K in Q2 2026.
  • Arbli™ wholesale unit sales rose 74% sequentially, supported by institutional formulary additions.
  • REZENOPY™ commercial launch in August 2026 contributed to revenue growth through initial wholesale shipments.
  • Company aims for profitability in 2027, citing historically high gross margins and expanding distribution channels.

Scienture's 256% sequential revenue growth highlights the accelerating commercial momentum of its expanding pharmaceutical portfolio. The successful launch of REZENOPY and continued sales growth of Arbli position the company to build a diversified, multi-product portfolio. This strategic inflection point underscores Scienture's progress in addressing unmet market needs in the specialty pharmaceutical sector.

Product Momentum
Whether Scienture can sustain the rapid revenue growth trajectory of Arbli and REZENOPY through 2027.
Market Penetration
The pace at which Scienture expands institutional adoption and healthcare provider engagement.
Profitability Path
How Scienture's historically high gross margins will support its goal of achieving profitability in 2027.